European Union - English - EMA (European Medicines Agency)

teva b.v. - rasagiline - parkinson disease - anti-parkinson drugs - rasagiline ratiopharm is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Canada - English - Health Canada

apotex inc - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors

Canada - English - Health Canada

apotex inc - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors

Canada - English - Health Canada

teva canada limited - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors

Canada - English - Health Canada

teva canada limited - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors

United States - English - NLM (National Library of Medicine)

bausch health us, llc - selegiline hydrochloride (unii: 6w731x367q) (selegiline - unii:2k1v7gp655) - selegiline hydrochloride 1.25 mg - zelapar is indicated as an adjunct in the management of patients with parkinson’s disease being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. there is no evidence from controlled studies that zelapar has any beneficial effect in the absence of concurrent levodopa therapy [see clinical studies (14) ]. zelapar is contraindicated in patients with: risk summary there are no adequate data on the developmental risk associated with the use of zelapar in pregnant women. in animal studies, administration of selegiline during pregnancy was associated with developmental toxicity (decreased embryofetal and postnatal offspring growth and survival) at doses greater than those used clinically. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage in the indicated population is u

Malta - English - Medicines Authority

evopharm s.r.o vyšehradská 12 bratislava, 851 06, slovakia - rasagiline - tablet - rasagiline 1 mg - anti-parkinson drugs

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord healthcare ltd - rasagiline - tablet - 1mg

Canada - English - Health Canada

ascend laboratories ltd - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors

Canada - English - Health Canada

ascend laboratories ltd - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors